XRTX — XORTX Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- CA$5.92m
- CA$4.33m
Annual cashflow statement for XORTX Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | C2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | Final | Final | Final |
| Net Income/Starting Line | -0.958 | -1.32 | -7.72 | -2.16 | -3.31 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 0.129 | -2.43 | -1.98 | -3.53 | -0.599 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.27 | -1.1 | 1.47 | -1.03 | 0.117 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -0.543 | -4.84 | -8.17 | -6.58 | -3.68 |
| Capital Expenditures | -0.011 | -0.032 | -0.046 | -0.046 | -0.039 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Cash from Investing Activities | -0.011 | -0.032 | -0.046 | -0.046 | -0.039 |
| Financing Cash Flow Items | -0.033 | -0.683 | -1.07 | -0.295 | -0.668 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.638 | 19.5 | 3.91 | -0.361 | 2.78 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.084 | 14.9 | -4.44 | -6.99 | -0.974 |